Histone Deacetylase Inhibitors Disrupt the Mitotic Spindle Assembly Checkpoint By Targeting Histone and Nonhistone Proteins

Advances in Cancer Research

Volumn 116, Issue , 2012, Pages 1-37

  Gabrielli, Brian ^a   Brown, Mellissa ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Aurora B; Chromosomal passenger complex; Plk1; Spindle assembly checkpoint; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA B KINASE; BUB1 RELATED PROTEIN; CENTROMERE PROTEIN A; COHESIN; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2D; CYCLIN E; HISTONE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; NONHISTONE PROTEIN; P21 ACTIVATED KINASE 1; SURVIVIN;

ACETYLATION; ANAPHASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL DIVISION; CELL FUNCTION; CENTROMERE; CONSTITUTIVE HETEROCHROMATIN; DEACETYLATION; DNA DAMAGE CHECKPOINT; DNA REPLICATION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE; MITOSIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SISTER CHROMATID; SISTER CHROMATID EXCHANGE; TUMOR CELL;

EID: 84867791940     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394387-3.00001-X     Document Type: Chapter

References (174)

1. Allshire R.C., Karpen G.H. Epigenetic regulation of centromeric chromatin: Old dogs, new tricks?. Nature Reviews. Genetics 2008, 9:923-937.
2. Andrews P.D., Knatko E., Moore W.J., Swedlow J.R. Mitotic mechanics: The auroras come into view. Current Opinion in Cell Biology 2003, 15:672-683.
3. Aoyagi S., Archer T.K. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biology 2005, 15:565-567.
4. Archer S.Y., Meng S., Shei A., Hodin R.A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:6791-6796.
5. Bannister A.J., Zegerman P., Partridge J.F., Miska E.A., Thomas J.O., Allshire R.C. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001, 410:120-124.
6. Becker M., Stolz A., Ertych N., Bastians H. Centromere localization of INCENP-Aurora B is sufficient to support spindle checkpoint function. Cell Cycle 2010, 9:1360-1372.
7. Beckouet F., Hu B., Roig M.B., Sutani T., Komata M., Uluocak P., et al. An Smc3 acetylation cycle is essential for establishment of sister chromatid cohesion. Molecular Cell 2010, 39:689-699.
8. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Molecular Cell 2008, 30:61-72.
9. Blagosklonny M.V., Robey R., Sackett D.L., Du L., Traganos F., Darzynkiewicz Z., et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Molecular Cancer Therapeutics 2002, 1:937-941.
10. Blower M.D., Sullivan B.A., Karpen G.H. Conserved organization of centromeric chromatin in flies and humans. Developmental Cell 2002, 2:319-330.
11. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 2006, 5:769-784.
12. Boutros R., Dozier C., Ducommun B. The when and wheres of CDC25 phosphatases. Current Opinion in Cell Biology 2006, 18:185-191.
13. Boyarchuk Y., Salic A., Dasso M., Arnaoutov A. Bub1 is essential for assembly of the functional inner centromere. The Journal of Cell Biology 2007, 176:919-928.
14. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
15. Burgess A.J., Pavey S., Warrener R., Hunter L.J., Piva T.J., Musgrove E.A., et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Molecular Pharmacology 2001, 60:828-837.
16. Burgess A., Ruefli A., Beamish H., Warrener R., Saunders N., Johnstone R., et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004, 23:6693-6701.
17. Carmena M., Pinson X., Platani M., Salloum Z., Xu Z., Clark A., et al. The chromosomal passenger complex activates Polo kinase at centromeres. PLoS Biology 2012, 10:e1001250.
18. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: A molecular definition. Oncogene 2004, 23:2825-2837.
19. Castedo M., Perfettini J.L., Roumier T., Valent A., Raslova H., Yakushijin K., et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004, 23:4362-4370.
20. Cha T.L., Chuang M.J., Wu S.T., Sun G.H., Chang S.Y., Yu D.S., et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clinical Cancer Research 2009, 15:840-850.
21. Chan G.K., Jablonski S.A., Sudakin V., Hittle J.C., Yen T.J. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. The Journal of Cell Biology 1999, 146:941-954.
22. Chan Y.W., Jeyaprakash A.A., Nigg E.A., Santamaria A. Aurora B controls kinetochore-microtubule attachments by inhibiting Ska complex-KMN network interaction. The Journal of Cell Biology 2012, 196:563-571.
23. Chia K., Beamish H., Jafferi K., Gabrielli B. The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity. Molecular Pharmacology 2010, 78:436-443.
24. Choi S., Reddy P. HDAC inhibition and graft versus host disease. Molecular Medicine 2011, 17:404-416.
25. Cimini D., Mattiuzzo M., Torosantucci L., Degrassi F. Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Molecular Biology of the Cell 2003, 14:3821-3833.
26. Dai J., Sullivan B.A., Higgins J.M. Regulation of mitotic chromosome cohesion by Haspin and Aurora B. Developmental Cell 2006, 11:741-750.
27. De Boer L., Oakes V., Beamish H., Giles N., Stevens F., Somodevilla-Torres M., et al. Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events. Oncogene 2008, 27:4261-4268.
28. de Carcer G. Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Research 2004, 64:5106-5112.
29. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. The Journal of Cell Biology 2003, 161:267-280.
30. Dobles M., Liberal V., Scott M.L., Benezra R., Sorger P.K. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000, 101:635-645.
31. Dowling M., Voong K.R., Kim M., Keutmann M.K., Harris E., Kao G.D. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biology & Therapy 2005, 4:197-206.
32. Drysdale M.J., Brough P.A., Massey A., Jensen M.R., Schoepfer J. Targeting Hsp90 for the treatment of cancer. Current Opinion in Drug Discovery & Development 2006, 9:483-495.
33. Ellis L., Hammers H., Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Letters 2009, 280:145-153.
34. Eot-Houllier G., Fulcrand G., Watanabe Y., Magnaghi-Jaulin L., Jaulin C. Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes & Development 2008, 22:2639-2644.
35. Eswaran J., Patnaik D., Filippakopoulos P., Wang F., Stein R.L., Murray J.W., et al. Structure and functional characterization of the atypical human kinase haspin. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:20198-20203.
36. Fava L.L., Kaulich M., Nigg E.A., Santamaria A. Probing the in vivo function of Mad1:C-Mad2 in the spindle assembly checkpoint. The EMBO Journal 2011, 30:3322-3336.
37. Fletcher J.I., Huang D.C. Controlling the cell death mediators Bax and Bak: Puzzles and conundrums. Cell Cycle 2008, 7:39-44.
38. Frew A.J., Johnstone R.W., Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Letters 2009, 280:125-133.
39. Fujita Y., Hayashi T., Kiyomitsu T., Toyoda Y., Kokubu A., Obuse C., et al. Priming of centromere for CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1. Developmental Cell 2007, 12:17-30.
40. Fung T.K., Ma H.T., Poon R.Y. Specialized roles of the two mitotic cyclins in somatic cells: Cyclin A as an activator of M phase-promoting factor. Molecular Biology of the Cell 2007, 18:1861-1873.
41. Gabrielli B., Chau Y.Q., Giles N., Harding A., Stevens F., Beamish H. Caffeine promotes apoptosis in mitotic spindle checkpoint-arrested cells. The Journal of Biological Chemistry 2007, 282:6954-6964.
42. Gascoigne K.E., Cheeseman I.M. Kinetochore assembly: If you build it, they will come. Current Opinion in Cell Biology 2011, 23:102-108.
43. Gascoigne K.E., Taylor S.S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008, 14:111-122.
44. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Molecular Cancer Therapeutics 2003, 2:151-163.
45. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
46. Gonzalez-Barrios R., Soto-Reyes E., Herrera L.A. Assembling pieces of the centromere epigenetics puzzle. Epigenetics 2012, 7:3-13.
47. Grabiec A.M., Tak P.P., Reedquist K.A. Function of histone deacetylase inhibitors in inflammation. Critical Reviews in Immunology 2011, 31:233-263.
48. Gray-Bablin J., Zalvide J., Fox M.P., Knickerbocker C.J., DeCaprio J.A., Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:15215-15220.
49. Gui C.Y., Ngo L., Xu W.S., Richon V.M., Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:1241-1246. Epub 2004 Jan 20.
50. Hauf S., Cole R.W., LaTerra S., Zimmer C., Schnapp G., Walter R., et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. The Journal of Cell Biology 2003, 161:281-294.
51. Hauf S., Roitinger E., Koch B., Dittrich C.M., Mechtler K., Peters J.M. Dissociation of cohesin from chromosome arms and loss of arm cohesion during early mitosis depends on phosphorylation of SA2. PLoS Biology 2005, 3:e69.
52. Henderson C., Brancolini C. Apoptotic pathways activated by histone deacetylase inhibitors: Implications for the drug-resistant phenotype. Drug Resistance Updates 2003, 6:247-256.
53. Hirose T., Sowa Y., Takahashi S., Saito S., Yasuda C., Shindo N., et al. p53-independent induction of Gadd45 by histone deacetylase inhibitor: Coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 2003, 22:7762-7773.
54. Hitomi T., Matsuzaki Y., Yokota T., Takaoka Y., Sakai T. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Letters 2003, 554:347-350.
55. Hori T., Amano M., Suzuki A., Backer C.B., Welburn J.P., Dong Y., et al. CCAN makes multiple contacts with centromeric DNA to provide distinct pathways to the outer kinetochore. Cell 2008, 135:1039-1052.
56. Howell B.J., McEwen B.F., Canman J.C., Hoffman D.B., Farrar E.M., Rieder C.L., et al. Cytoplasmic dynein/dynactin drives kinetochore protein transport to the spindle poles and has a role in mitotic spindle checkpoint inactivation. The Journal of Cell Biology 2001, 155:1159-1172.
57. Huang P.H., Chen C.H., Chou C.C., Sargeant A.M., Kulp S.K., Teng C.M., et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Molecular Pharmacology 2011, 79:197-206.
58. Huang H.C., Shi J., Orth J.D., Mitchison T.J. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009, 16:347-358.
59. Huang L., Sowa Y., Sakai T., Pardee A.B. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000, 19:5712-5719.
60. Ishii S., Kurasawa Y., Wong J., Yu-Lee L.Y. Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:4179-4184.
61. Jacobs S.A., Taverna S.D., Zhang Y., Briggs S.D., Li J., Eissenberg J.C., et al. Specificity of the HP1 chromo domain for the methylated N-terminus of histone H3. The EMBO Journal 2001, 20:5232-5241.
62. Jansen L.E., Black B.E., Foltz D.R., Cleveland D.W. Propagation of centromeric chromatin requires exit from mitosis. The Journal of Cell Biology 2007, 176:795-805.
63. Jin S., Antinore M.J., Lung F.D., Dong X., Zhao H., Fan F., et al. The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. The Journal of Biological Chemistry 2000, 275:16602-16608.
64. Kasuboski J.M., Bader J.R., Vaughan P.S., Tauhata S.B., Winding M., Morrissey M.A., et al. Zwint-1 is a novel Aurora B substrate required for the assembly of a dynein-binding platform on kinetochores. Molecular Biology of the Cell 2011, 22:3318-3330.
65. Kawashima S.A., Yamagishi Y., Honda T., Ishiguro K., Watanabe Y. Phosphorylation of H2A by Bub1 prevents chromosomal instability through localizing shugoshin. Science 2010, 327:172-177.
66. Kelly A.E., Ghenoiu C., Xue J.Z., Zierhut C., Kimura H., Funabiki H. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science 2010, 330:235-239.
67. Kim Y.K., Han J.W., Woo Y.N., Chun J.K., Yoo J.Y., Cho E.J., et al. Expression of p21(WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene 2003, 22:6023-6031.
68. Kim Y., Holland A.J., Lan W., Cleveland D.W. Aurora kinases and protein phosphatase 1 mediate chromosome congression through regulation of CENP-E. Cell 2010, 142:444-455.
69. Kiyomitsu T., Iwasaki O., Obuse C., Yanagida M. Inner centromere formation requires hMis14, a trident kinetochore protein that specifically recruits HP1 to human chromosomes. The Journal of Cell Biology 2010, 188:791-807.
70. Kiyomitsu T., Obuse C., Yanagida M. Human Blinkin/AF15q14 is required for chromosome alignment and the mitotic checkpoint through direct interaction with Bub1 and BubR1. Developmental Cell 2007, 13:663-676.
71. Kline S.L., Cheeseman I.M., Hori T., Fukagawa T., Desai A. The human Mis12 complex is required for kinetochore assembly and proper chromosome segregation. The Journal of Cell Biology 2006, 173:9-17.
72. Krauer K.G., Burgess A., Buck M., Flanagan J., Sculley T.B., Gabrielli B. The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 2004, 23:1342-1353.
73. Lallemand F., Courilleau D., Buquet-Fagot C., Atfi A., Montagne M.N., Mester J. Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication. Experimental Cell Research 1999, 247:432-440.
74. Lee J.H., Choy M.L., Ngo L., Venta-Perez G., Marks P.A. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:19629-19634.
75. Leggatt G.R., Gabrielli B. Histone deacetylase inhibitors in the generation of the anti-tumour immune response. Immunology and Cell Biology 2012, 90:33-38.
76. Li C., Andrake M., Dunbrack R., Enders G.H. A bifunctional regulatory element in human somatic Wee1 mediates cyclin A/Cdk2 binding and Crm1-dependent nuclear export. Molecular and Cellular Biology 2010, 30:116-130.
77. Li G., Jiang H., Chang M., Xie H., Hu L. HDAC6 alpha-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases. Journal of the Neurological Sciences 2011, 304:1-8.
78. Li Y., Kao G.D., Garcia B.A., Shabanowitz J., Hunt D.F., Qin J., et al. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes & Development 2006, 20:2566-2579.
79. Lindemann R.K., Gabrielli B., Johnstone R.W. Histone-Deacetylase Inhibitors for the Treatment of Cancer. Cell Cycle 2004, 3:779-788.
80. Lindemann R.K., Newbold A., Whitecross K.F., Cluse L.A., Frew A.J., Ellis L., et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:8071-8076.
81. Lindqvist A., Rodriguez-Bravo V., Medema R.H. The decision to enter mitosis: Feedback and redundancy in the mitotic entry network. The Journal of Cell Biology 2009, 185:193-202.
82. Losada A. The regulation of sister chromatid cohesion. Biochimica et Biophysica Acta 2008, 1786:41-48.
83. Lyman S.K., Crawley S.C., Gong R., Adamkewicz J.I., McGrath G., Chew J.Y., et al. High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888. PLoS One 2011, 6:e17692.
84. Ma Y., Cai S., Lu Q., Lu X., Jiang Q., Zhou J., et al. Inhibition of protein deacetylation by trichostatin A impairs microtubule-kinetochore attachment. Cellular and Molecular Life Sciences 2008, 65:3100-3109.
85. Macurek L., Lindqvist A., Medema R.H. Aurora-A and hBora join the game of Polo. Cancer Research 2009, 69:4555-4558.
86. Magnaghi-Jaulin L., Eot-Houllier G., Fulcrand G., Jaulin C. Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Research 2007, 67:6360-6367.
87. Maity A., Hwang A., Janss A., Phillips P., McKenna W.G., Muschel R.J. Delayed cyclin B1 expression during the G2 arrest following DNA damage. Oncogene 1996, 13:1647-1657.
88. Manke I.A., Nguyen A., Lim D., Stewart M.Q., Elia A.E., Yaffe M.B. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Molecular Cell 2005, 17:37-48.
89. Maresca T.J. Cell division: Aurora B illuminates a checkpoint pathway. Current Biology 2011, 21:R557-R559.
90. Maresca T.J., Salmon E.D. Welcome to a new kind of tension: Translating kinetochore mechanics into a wait-anaphase signal. Journal of Cell Science 2010, 123:825-835.
91. Martin C., Zhang Y. The diverse functions of histone lysine methylation. Nature Reviews. Molecular Cell Biology 2005, 6:838-849.
92. Matalon S., Rasmussen T.A., Dinarello C.A. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Molecular Medicine 2011, 17:466-472.
93. Mateo F., Vidal-Laliena M., Canela N., Busino L., Martinez-Balbas M.A., Pagano M., et al. Degradation of cyclin A is regulated by acetylation. Oncogene 2009, 28:2654-2666.
94. McConnell B.B., Gregory F.J., Stott F.J., Hara E., Peters G. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Molecular and Cellular Biology 1999, 19:1981-1989.
95. Mikhailov A., Shinohara M., Rieder C.L. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. The Journal of Cell Biology 2004, 166:517-526.
96. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:540-545.
97. Musacchio A., Salmon E.D. The spindle-assembly checkpoint in space and time. Nature Reviews. Molecular Cell Biology 2007, 8:379-393.
98. Nasmyth K. Cohesin: A catenase with separate entry and exit gates?. Nature Cell Biology 2011, 13:1170-1177.
99. Nezi L., Musacchio A. Sister chromatid tension and the spindle assembly checkpoint. Current Opinion in Cell Biology 2009, 21:785-795.
100. Nightingale K.P., Gendreizig S., White D.A., Bradbury C., Hollfelder F., Turner B.M. Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. The Journal of Biological Chemistry 2007, 282:4408-4416.
101. Niida H., Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006, 21:3-9.
102. Nitta M., Kobayashi O., Honda S., Hirota T., Kuninaka S., Marumoto T., et al. Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene 2004, 23:6548-6558.
103. Nome R.V., Bratland A., Harman G., Fodstad O., Andersson Y., Ree A.H. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Molecular Cancer Therapeutics 2005, 4:1231-1238.
104. Obuse C., Iwasaki O., Kiyomitsu T., Goshima G., Toyoda Y., Yanagida M. A conserved Mis12 centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1. Nature Cell Biology 2004, 6:1135-1141.
105. Ohtsubo M., Theodoras A.M., Schumacher J., Roberts J.M., Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Molecular and Cellular Biology 1995, 15:2612-2624.
106. Ozdag H., Teschendorff A.E., Ahmed A.A., Hyland S.J., Blenkiron C., Bobrow L., et al. Differential expression of selected histone modifier genes in human solid cancers. BioMed Central Genomics 2006, 7:90.
107. Pagano M., Pepperkok R., Verde F., Ansorge W., Draetta G. Cyclin A is required at two points in the human cell cycle. The EMBO Journal 1992, 11:961-971.
108. Park J.H., Jong H.S., Kim S.G., Jung Y., Lee K.W., Lee J.H., et al. Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. Journal of Molecular Medicine 2008, 86:117-128.
109. Park J.H., Jung Y., Kim T.Y., Kim S.G., Jong H.S., Lee J.W., et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clinical Cancer Research 2004, 10:5271-5281.
110. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:3697-3702.
111. Peart M.J., Tainton K.M., Ruefli A.A., Dear A.E., Sedelies K.A., O'Reilly L.A., et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Research 2003, 63:4460-4471.
112. Peters A.H., O'Carroll D., Scherthan H., Mechtler K., Sauer S., Schofer C., et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001, 107:323-337.
113. Petronczki M., Lenart P., Peters J.M. Polo on the rise-From mitotic entry to cytokinesis with Plk1. Developmental Cell 2008, 14:646-659.
114. Pines J. Cubism and the cell cycle: The many faces of the APC/C. Nature Reviews. Molecular Cell Biology 2011, 12:427-438.
115. Potapova T.A., Daum J.R., Byrd K.S., Gorbsky G.J. Fine tuning the cell cycle: Activation of the Cdk1 inhibitory phosphorylation pathway during mitotic exit. Molecular Biology of the Cell 2009, 20:1737-1748.
116. Potapova T.A., Daum J.R., Pittman B.D., Hudson J.R., Jones T.N., Satinover D.L., et al. The reversibility of mitotic exit in vertebrate cells. Nature 2006, 440:954-958.
117. Prystowsky M.B., Adomako A., Smith R.V., Kawachi N., McKimpson W., Atadja P., et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. The Journal of Pathology 2009, 218:467-477.
118. Przewloka M.R., Glover D.M. The kinetochore and the centromere: A working long distance relationship. Annual Review of Genetics 2009, 43:439-465.
119. Qiu L., Burgess A., Fairlie D.P., Leonard H., Parsons P.G., Gabrielli B.G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Molecular Biology of the Cell 2000, 11:2069-2083.
120. Qiu L., Kelso M.J., Hansen C., West M.L., Fairlie D.P., Parsons P.G. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. British Journal of Cancer 1999, 80:1252-1258.
121. Rahman R., Grundy R. Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. International Journal of Cancer 2011, 129:2765-2774.
122. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10014-10019.
123. Rieder C.L., Maiato H. Stuck in division or passing through: What happens when cells cannot satisfy the spindle assembly checkpoint. Developmental Cell 2004, 7:637-651.
124. Robbins A.R., Jablonski S.A., Yen T.J., Yoda K., Robey R., Bates S.E., et al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 2005, 4:717-726.
125. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. The Journal of Biological Chemistry 1999, 274:34940-34947.
126. Sandor V., Senderowicz A., Mertins S., Sackett D., Sausville E., Blagosklonny M.V., et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. British Journal of Cancer 2000, 83:817-825.
127. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Histone acetylation-mediated regulation of genes in leukaemic cells. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Cancer Research 2003, 63:3735-3742.
128. Satyanarayana A., Kaldis P. Mammalian cell-cycle regulation: Several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28:2925-2939.
129. Schmiedeberg L., Weisshart K., Diekmann S., Meyer Zu Hoerste G., Hemmerich P. High- and low-mobility populations of HP1 in heterochromatin of mammalian cells. Molecular Biology of the Cell 2004, 15:2819-2833.
130. Schrump D.S. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: Mechanisms and potential clinical implications. Clinical Cancer Research 2009, 15:3947-3957.
131. Senese S., Zaragoza K., Minardi S., Muradore I., Ronzoni S., Passafaro A., et al. Role for histone deacetylase 1 in human tumor cell proliferation. Molecular Cell Biology 2007, 27:4784-4795.
132. Shakespear M.R., Halili M.A., Irvine K.M., Fairlie D.P., Sweet M.J. Histone deacetylases as regulators of inflammation and immunity. Trends in Immunology 2011, 32:335-343.
133. Sherr C.J. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Research 2000, 60:3689-3695.
134. Shi J., Orth J.D., Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Research 2008, 68:3269-3276.
135. Shin H.J., Baek K.H., Jeon A.H., Kim S.J., Jang K.L., Sung Y.C., et al. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 2003, 22:3853-3858.
136. Skoufias D.A., Indorato R.L., Lacroix F., Panopoulos A., Margolis R.L. Mitosis persists in the absence of Cdk1 activity when proteolysis or protein phosphatase activity is suppressed. The Journal of Cell Biology 2007, 179:671-685.
137. Stevens F.E., Beamish H., Warrener R., Gabrielli B. Histone deacetylase inhibitors induce mitotic slippage. Oncogene 2008, 27:1345-1354.
138. Stimpson K.M., Sullivan B.A. Epigenomics of centromere assembly and function. Current Opinion in Cell Biology 2010, 22:772-780.
139. Strausfeld U.P., Howell M., Descombes P., Chevalier S., Rempel R.E., Adamczewski J., et al. Both cyclin A and cyclin E have S-phase promoting (SPF) activity in Xenopus egg extracts. Journal of Cell Science 1996, 109:1555-1563.
140. Subramanian C., Opipari A.W., Bian X., Castle V.P., Kwok R.P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:4842-4847.
141. Sudo T., Nitta M., Saya H., Ueno N.T. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Research 2004, 64:2502-2508.
142. Sullivan B.A., Karpen G.H. Centromeric chromatin exhibits a histone modification pattern that is distinct from both euchromatin and heterochromatin. Nature Structural & Molecular Biology 2004, 11:1076-1083.
143. Taddei A., Maison C., Roche D., Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nature Cell Biology 2001, 3:114-120.
144. Tao W., South V.J., Zhang Y., Davide J.P., Farrell L., Kohl N.E., et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005, 8:49-59.
145. Taylor S.S., McKeon F. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 1997, 89:727-735.
146. Terrano D.T., Upreti M., Chambers T.C. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Molecular and Cellular Biology 2010, 30:640-656.
147. Torras-Llort M., Moreno-Moreno O., Azorin F. Focus on the centre: The role of chromatin on the regulation of centromere identity and function. The EMBO Journal 2009, 28:2337-2348.
148. Tunquist B.J., Woessner R.D., Walker D.H. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Molecular Cancer Therapeutics 2010, 9:2046-2056.
149. Vadlamudi R.K., Bagheri-Yarmand R., Yang Z., Balasenthil S., Nguyen D., Sahin A.A., et al. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004, 5:575-585.
150. Vagnarelli P., Earnshaw W.C. Chromosomal passengers: The four-dimensional regulation of mitotic events. Chromosoma 2004, 113:211-222.
151. van de Weerdt B.C., van Vugt M.A., Lindon C., Kauw J.J., Rozendaal M.J., Klompmaker R., et al. Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Molecular and Cellular Biology 2005, 25:2031-2044.
152. Varetti G., Guida C., Santaguida S., Chiroli E., Musacchio A. Homeostatic control of mitotic arrest. Molecular Cell 2011, 44:710-720.
153. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases: versatile regulators. Trends in Genetics 2003, 19:286-293.
154. Vogel C., Hager C., Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Research 2007, 67:339-345.
155. Vogel C., Kienitz A., Muller R., Bastians H. The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. The Journal of Biological Chemistry 2005, 280:4025-4028.
156. Wang E., Ballister E.R., Lampson M.A. Aurora B dynamics at centromeres create a diffusion-based phosphorylation gradient. The Journal of Cell Biology 2011, 194:539-549.
157. Wang F., Dai J., Daum J.R., Niedzialkowska E., Banerjee B., Stukenberg P.T., et al. Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science 2010, 330:231-235.
158. Warrener R., Beamish H., Burgess A., Waterhouse N.J., Giles N., Fairlie D., et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. The FASEB Journal 2003, 17:1550-1552.
159. Warrener R., Chia K., Warren W.D., Brooks K., Gabrielli B. Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone h3 lysine 9 acetylation and methylation. Molecular Pharmacology 2010, 78:384-393.
160. Wassmann K., Benezra R. Mitotic checkpoints: From yeast to cancer. Current Opinion in Genetics & Development 2001, 11:83-90.
161. Weaver B.A., Cleveland D.W. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005, 8:7-12.
162. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
163. Weichert W., Roske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clinical Cancer Research 2008, 14:1669-1677.
164. Westhorpe F.G., Tighe A., Lara-Gonzalez P., Taylor S.S. p31comet-mediated extraction of Mad2 from the MCC promotes efficient mitotic exit. Journal of Cell Science 2011, 124:3905-3916.
165. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315:856-859.
166. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. The Journal of Biological Chemistry 2006, 281:13548-13558.
167. Xiao H., Hasegawa T., Isobe K. p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. The Journal of Biological Chemistry 2000, 275:1371-1376.
168. Xu Z., Cetin B., Anger M., Cho U.S., Helmhart W., Nasmyth K., et al. Structure and function of the PP2A-shugoshin interaction. Molecular Cell 2009, 35:426-441.
169. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
170. Yamagishi Y., Honda T., Tanno Y., Watanabe Y. Two histone marks establish the inner centromere and chromosome bi-orientation. Science 2010, 330:239-243.
171. Yokota T., Matsuzaki Y., Miyazawa K., Zindy F., Roussel M.F., Sakai T. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 2004, 26:26.
172. Zajac M., Moneo M.V., Carnero A., Benitez J., Martinez-Delgado B. Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Molecular Cancer Therapeutics 2008, 7:2358-2366.
173. Zeitlin S.G., Shelby R.D., Sullivan K.F. CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. The Journal of Cell Biology 2001, 155:1147-1157.
174. Zhang X., Lan W., Ems-McClung S.C., Stukenberg P.T., Walczak C.E. Aurora B phosphorylates multiple sites on mitotic centromere-associated kinesin to spatially and temporally regulate its function. Molecular Biology of the Cell 2007, 18:3264-3276.